Related Experiment Videos
Intraperitoneal chemotherapy for ovarian cancer
Gregory Friberg1, Gini Fleming
1The University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637-1470, USA.
Current Oncology Reports
|October 3, 2003
Summary
Intraperitoneal chemotherapy shows survival benefits for ovarian cancer patients but isn't standard care due to delivery issues and toxicity. Further research is needed to optimize this treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian cancer frequently recurs within the abdomen, causing significant morbidity and mortality.
- Intraperitoneal chemotherapy offers high drug concentrations and prolonged exposure at the peritoneal surface.
Purpose of the Study:
- To evaluate the role and challenges of intraperitoneal chemotherapy in ovarian cancer treatment.
- To identify reasons for its limited adoption despite demonstrated survival benefits.
Main Methods:
- Review of three large randomized trials investigating intraperitoneal chemotherapy in optimally debulked ovarian cancer patients.
- Analysis of factors hindering the widespread clinical use of intraperitoneal chemotherapy.
Main Results:
- Intraperitoneal chemotherapy improved survival in optimally debulked patients when used as part of front-line therapy.
- Technical challenges and the toxicity profile of intraperitoneal cisplatin contributed to its limited adoption compared to intravenous carboplatin.
Conclusions:
- Despite survival benefits, intraperitoneal chemotherapy is not standard for ovarian cancer.
- Future research should focus on optimizing regimens, minimizing side effects, and exploring novel intraperitoneal therapies (biologic, immunologic, gene).